These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 20410684

  • 1. Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
    Demir M, Göktürk S, Oztürk NA, Serin E, Yilmaz U.
    Digestion; 2010; 82(1):47-53. PubMed ID: 20410684
    [Abstract] [Full Text] [Related]

  • 2. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N.
    Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
    [Abstract] [Full Text] [Related]

  • 3. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS, Parlak E, Filik L, Yolcu OF, Odemiş B, Ulker A, Saşmaz N, Ozden A, Sahin B.
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
    Uygun A, Kadayifci A, Safali M, Ilgan S, Bagci S.
    J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study.
    Demir M, Gokturk HS, Ozturk NA, Serin E, Yilmaz U.
    Am J Med Sci; 2009 Dec; 338(6):459-64. PubMed ID: 19884816
    [Abstract] [Full Text] [Related]

  • 6. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
    Uygun A, Ozel AM, Yildiz O, Aslan M, Yesilova Z, Erdil A, Bagci S, Gunhan O.
    J Gastroenterol Hepatol; 2008 Jan; 23(1):42-5. PubMed ID: 17559359
    [Abstract] [Full Text] [Related]

  • 7. Bismuth-based therapies for the first step eradication of Helicobacter pylori.
    Sezgin O, Altintaş E, Uçbilek E, Tataroğlu C.
    Turk J Gastroenterol; 2006 Jun; 17(2):90-3. PubMed ID: 16830288
    [Abstract] [Full Text] [Related]

  • 8. Effect of sequential treatment as a first-line therapy for Helicobacter pylori eradication in patients with diabetes mellitus.
    Ataseven H, Demir M, Gen R.
    South Med J; 2010 Oct; 103(10):988-92. PubMed ID: 20818305
    [Abstract] [Full Text] [Related]

  • 9. 14-day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure in Thailand.
    Thong-Ngam D, Mahachai V.
    J Med Assoc Thai; 2006 Sep; 89 Suppl 3():S119-25. PubMed ID: 17718277
    [Abstract] [Full Text] [Related]

  • 10. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY, Kim N, Park KS, Kim HJ, Park SM, Baik GH, Shim KN, Oh JH, Choi SC, Kim SE, Kim WH, Park SY, Kim GH, Lee BE, Jo Y, Hong SJ.
    BMC Gastroenterol; 2016 Jul 26; 16(1):79. PubMed ID: 27460100
    [Abstract] [Full Text] [Related]

  • 11. Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection.
    de Boer SY, v d Meeberg PC, Siem H, de Boer WA.
    Neth J Med; 2003 Jun 26; 61(6):218-22. PubMed ID: 12956102
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, Wang HM, Chen WC, Sun WC, Tsai KW, Hsu PI.
    Antimicrob Agents Chemother; 2017 Nov 26; 61(11):. PubMed ID: 28807915
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of ranitidine bismuth citrate plus amoxycillin and clarithromycin as first- or second-line therapy to cure Helicobacter pylori infection.
    Tursi A, Brandimarte G, Giorgetti G, Modeo ME, Gigliobianco A.
    Hepatogastroenterology; 2002 Nov 26; 49(46):1006-9. PubMed ID: 12143188
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
    Zheng Q, Pan Y, Zhang L, Xiao SD.
    Chin J Dig Dis; 2005 Nov 26; 6(4):202-5. PubMed ID: 16246231
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin.
    Cetinkaya ZA, Sezikli M, Güzelbulut F, Coşgun S, Düzgün S, Kurdaş OO.
    Helicobacter; 2010 Apr 26; 15(2):143-7. PubMed ID: 20402816
    [Abstract] [Full Text] [Related]

  • 20. Effect of Helicobacter pylori eradication on glycaemia control in patients with type 2 diabetes mellitus and comparison of two therapeutic regimens.
    Vafaeimanesh J, Rajabzadeh R, Ahmadi A, Moshtaghi M, Banikarim S, Hajiebrahimi S, Seyyedmajidi M.
    Arab J Gastroenterol; 2013 Jun 26; 14(2):55-8. PubMed ID: 23820501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.